<DOC>
	<DOCNO>NCT02923739</DOCNO>
	<brief_summary>The goal clinical research study learn add emactuzumab combination paclitaxel bevacizumab help control relapse refractory ovarian , Fallopian tube , primary peritoneal cancer . The safety side effect drug combination also study .</brief_summary>
	<brief_title>Induction Discontinuation Trial Emactuzumab Following Paclitaxel Bevacizumab Patients With Platinum-Resistant , Epithelial Ovarian , Fallopian Tube Primary Peritoneal Cancer - REDIRECT</brief_title>
	<detailed_description>Part 1 : Study Groups : If find eligible take part study , assign study group base join study . Up 9 participant enrol Part 1 study , 112 participant enrol Part 2 . You Part 1 , receive paclitaxel , bevacizumab , emactuzumab check high tolerable dose . Study Drug Administration : Every study cycle 28 day . You receive paclitaxel vein 1 hour Days 1 , 8 , 15 , 22 , cycle . You receive bevacizumab emactuzumab vein Days 1 15 cycle . Bevacizumab give 90 minute first time give . Doses give short time side effect see . Emactuzumab give 30 minute time give study . If disease get bad agree , core biopsy , take study , offer treatment option . Length Study : You may continue receive study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Study Visits : On Day 1 every cycle : - You physical exam . - Blood ( 2½ tablespoon ) draw routine testing , check , heart function , tumor marker test . - Urine collect routine test . - Blood ( 1 teaspoon time ) drawn dose pharmacokinetic ( PK ) test . PK test measure much study drug body different time point . On Day 1 Cycle 2 every 8 week , either CT MRI chest , abdomen , pelvis . On Days 8 , 15 , 22 every cycle , blood ( 2 tablespoon ) draw routine test . Day 1 Cycles 1 , 3 , 5 , blood ( 1 teaspoon ) drawn dose pharmacodynamic ( PD ) biomarker test . PD test measure level study drug body may affect disease . If doctor think need , may EKG time study . End Treatment : After stop receiving study drug , follow test procedure perform : - You physical exam . - Blood ( 2 ½ tablespoon ) draw routine test , check heart function , tumor marker test . - Urine collect routine test . - You either CT MRI chest , abdomen , pelvis . - Blood ( 1 teaspoon ) drawn PD test . Follow-Up Visit : About 30 day ( +/- 5 day ) receive last dose study drug : - You physical exam . - Blood ( 2 ½ tablespoon ) draw routine tumor marker test . Information health status continue collect medical record 5 year leave study . This investigational study . Bevacizumab paclitaxel FDA approve commercially available treatment several type cancer . This drug combination approve treatment epithelial ovarian , primary peritoneal , fallopian tube cancer . Emactuzumab FDA approve commercially available . The addition emactuzumab combination bevacizumab paclitaxel investigational currently use research purpose . The doctor explain study drug design work . Up 9 participant enrol Part 1 multicenter study . All take part MD Anderson . Up 112 participant enrol Part 2 study . Up 74 take part MD Anderson . Part 2 : Study Groups : If find eligible take part study , assign study group base join study . Up 9 participant enrol Part 1 study , 112 participant enrol Part 2 . You Part 2 . You begin study receive paclitaxel bevacizumab 8 week . After , randomly assign ( flip coin ) 1 2 study arm . - If Arm 1 , receive paclitaxel bevacizumab . - If Arm 2 , receive paclitaxel , bevacizumab , emactuzumab . Study Drug Administration : Every study cycle 28 day . You receive paclitaxel vein 1 hour Days 1 , 8 , 15 22 2 cycle receive bevacizumab vein Days 1 15 2 cycle . This call Part 2A . The status disease check . If disease get bad agree , core biopsy , take study , offer treatment option . If disease improves , continue receive treatment Part 2A continue onto Part 2B . If disease stable , core biopsy continue onto Part 2B . - If Arm 1 Part 2B , receive paclitaxel vein 1 hour Days 1 , 8 , 15 , 22 cycle receive bevacizumab vein Days 1 15 cycle . - If Arm 2 Part 2B , receive paclitaxel vein 1 hour Days 1 , 8 , 15 , 22 cycle receive bevacizumab emactuzumab vein Days 1 15 cycle . Length Study : You may continue receive study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Study Visits : On Day 1 every cycle : - You physical exam . - Blood ( 2½ tablespoon ) draw routine testing , check , heart function , tumor marker test . - Urine collect routine test . - If Part 2B , blood ( 1 teaspoon time ) drawn dose pharmacokinetic ( PK ) test . PK test measure much study drug body different time point . On Day 1 Cycle 2 every 8 week , either CT MRI chest , abdomen , pelvis . On Days 8 , 15 , 22 every cycle , blood ( 2 tablespoon ) draw routine test . If Part 2A , Day 22 Cycle 2 , blood ( 1 teaspoon ) drawn dose PD testing . If Part 2B , Day 1 Cycles 3 5 , blood ( 1 teaspoon ) drawn dose PD testing . If doctor think need , may EKG time study . End Treatment : After stop receiving study drug , follow test procedure perform : - You physical exam . - Blood ( 2 ½ tablespoon ) draw routine test , check heart function , tumor marker test . - Urine collect routine test . - You either CT MRI chest , abdomen , pelvis . - If Part 2B , blood ( 1 teaspoon ) drawn PD test . Follow-Up Visit : About 30 day ( +/- 5 day ) receive last dose study drug : - You physical exam . - Blood ( 2 ½ tablespoon ) draw routine tumor marker test . Information health status continue collect medical record 5 year leave study . This investigational study . Bevacizumab paclitaxel FDA approve commercially available treatment several type cancer . This drug combination approve treatment epithelial ovarian , primary peritoneal , Fallopian tube cancer . Emactuzumab FDA approve commercially available . The addition emactuzumab combination bevacizumab paclitaxel investigational currently use research purpose . The doctor explain study drug design work . Up 9 participant enrol Part 1 multicenter study . All take part MD Anderson . Up 112 participant enrol Part 2 study . Up 74 take part MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Signed informed consent obtain prior initiation studyspecific procedure treatment confirmation patient 's awareness willingness comply study requirement ( inclusive 2 biopsy , one baseline qualify , one prerandomization part 2B ) . 2 . Women 18 year age old . 3 . Histologically confirm documented disease include : adenocarcinoma NOS ( Not Otherwise Specified ) , clear cell adenocarcinoma , endometrioid adenocarcinoma , malignant Brenner 's tumor , mixed epithelial carcinoma , mucinous adenocarcinoma , serous adenocarcinoma , transitional cell carcinoma , undifferentiated carcinoma . 4 . Patients must platinumresistant disease , ( define progression within &lt; 6 month completion minimum 4 platinum therapy cycle . The date calculate last administered dose platinum therapy ) . 5 . Patients must disease measurable accord RECIST 1.1 assessable accord GCIG CA125 criterion require chemotherapy treatment . Patients must two measurable target lesion . a. Measurable disease define least one lesion accurately measure least one dimension ( long dimension record ) . Each 'target ' lesion must &gt; /= 20 mm measure conventional technique , include palpation , plain xray , CT , MRI , &gt; /= 10 mm measure spiral CT. 6 . Have performance status 0 1 ECOG Performance Scale . 7 . Newly obtain core excisional biopsy tumor lesion Part 2A qualify , one prerandomization biopsy part 2B . 8 . Adequate organ function determine follow laboratory value : . Absolute neutrophil count &gt; /=1,500 /mcL . b. Platelets &gt; /=100,000 / mcL c. Hemoglobin &gt; /=9 g/dL &gt; /=5.6 mmol/L . d. Creatinine Clearance &gt; /=60 mL/min subject creatinine level &gt; 1.5 X institutional ULN . e. Total Bilirubin &lt; /= 1.5 X ULN OR Direct bilirubin &lt; /= ULN subject total bilirubin level &gt; 1.5 ULN . f. AST ( SGOT ) ALT ( SGPT ) &lt; /= 2.5 X ULN OR &lt; /= 5 X ULN subject liver metastasis . g. INR/PT &lt; /=1.5 X ULN ( unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant ) . h. PTT &lt; /=1.5 X ULN ( unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant . 9 . Life expectancy &gt; /= 12 week . 1 . Patients whose disease refractory previous platinum treatment . Refractory disease define patient progressed precede platinum treatment . 2 . Nonepithelial , include malignant mixed Müllerian tumor . 3 . Ovarian tumor low malignant potential ( i.e . borderline tumor ) . 4 . History clinically active malignancy within 5 year enrollment , except tumor negligible risk metastasis death , adequately control basalcell carcinoma squamouscell carcinoma skin carcinoma situ cervix breast , early stage endometrial cancer ( stage IA/B , Grade 1 2 , endometrioid histology ) . 5 . Previous treatment &gt; 2 anticancer regimen . 6 . Any approved anticancer therapy , include chemotherapy hormonal therapy , within 3 week prior initiation study treatment , follow exception : Hormonereplacement therapy oral contraceptive Tyrosine kinase inhibitor ( TKIs ) discontinue &gt; 7 day prior Cycle 1 , Day 1 ; screen scan must obtain discontinuation prior TKIs . 7 . Any prior radiotherapy pelvis abdomen . 8 . Surgical procedure ( include open biopsy , surgical resection , wound revision , major surgery involve entry body cavity ) significant traumatic injury within 28 day prior study enrollment , anticipation need major surgical procedure course study . Minor surgical procedure include placement vascular access device , within 2 day first study treatment . 9 . Previous exposure murine CA125 antibody ( applicable patient nonmeasurable disease RECIST ) . 10 . Current recent ( within 10 day prior first study drug dose ) chronic daily treatment aspirin ( &gt; 325 mg/day ) . 11 . Current recent treatment another investigational drug within 30 day first study treat¬ment dose early participation study . 12 . Treatment systemic immunosuppressive medication ( include , limited , prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antiTNF agent within 2 week prior Cycle 1 , Day 1 . Patients receive acute and/or lowrolment , anticipation need major surgical , onetime dose dexamethasone nausea chronic use &lt; /= 10 mg/day prednisone doseequivalent corticosteroid ) may enrol study discussion approval Medical Monitor . The use inhale corticosteroid mineralocorticoid ( e.g. , fludrocortisone ) allow . Prior corticosteroid anticancer therapy within minimum 14 day first receipt study drug . 13 . Received therapeutic oral IV antibiotic within 2 week prior Cycle 1 , Day 1 . Patients receive prophylactic antibiotic ( e.g. , prevention urinary tract infection chronic obstructive pulmonary disease ) eligible . 14 . Patients urine dipstick proteinuria &gt; 2+ . Patients &gt; /=2+ proteinuria baseline dipstick analysis undergo 24hour urine collection must demonstrate &lt; /=1 g protein 24hour urine . Alternatively , proteinuria test perform accord local standard . 15 . Patients know autoimmune disease . 16 . Patients known history HIV , HBV HCV infection . 17 . Patient receive organ transplant . 18 . Patient history hematological malignancy within last 5 year prior study entry . Prior allogenic bone marrow transplantation prior solid organ transplantation . 19 . History active autoimmune disease include , limited , systemic lupus erythematous , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , Bell 's palsy , GuillainBarré syndrome , multiple sclerosis , vasculitis glomerulonephritis . Patients autoimmune thyroid disease stable thyroid replacement regimen ; control vitiligo , eczema , psoriasis , seborrhoic dermatitis dermatologic manifestation ; control Type I diabetes stable insulin regimen may eligible study approval Medical Monitor . 20 . History evidence upon physical / neurological examination CNS disease unrelated cancer , unless adequately treat standard medical therapy ( e.g . uncontrolled seizure ) . 21 . Symptomatic CNS metastasis . 22 . Preexisting peripheral neuropathy &gt; /= CTC grade 2 patient receive prior paclitaxel . 23 . Spinal cord compression definitively treat surgery and/or radiation previously diagnose treat spinal cord compression without evidence disease clinically stable &gt; /= 2 week prior screen . 24 . Increased correct QT ( QTc ) interval ( QTc &gt; 470 m ) , patient baseline rest bradycardia &lt; 45 bpm , baseline rest tachycardia &gt; 100 bpm . 25 . Family history long QT syndrome risk factor torsades de pointes , and/or use concomitant medication prolong QT/QTc interval . 26 . Signs symptoms serious active infection require oral i.v . antibiotic within 2 week prior Cycle 1 Day 1 and/or hospitalization study entry include , limited , hospitalization complication infection , bacteremia , active tuberculosis severe pneumonia.. 27 . Pregnant lactating female . Serum pregnancy test assess within 7 day prior study treatment start , within 14 day ( confirmatory urine pregnancy test within 7 day prior study treatment start ) . 28 . For woman postmenopausal ( &lt; 12 month non therapyinduced amenorrhea , identify cause menopause ) undergone surgical sterilization ( removal ovary and/or uterus ) : agreement remain abstinent ( refrain heterosexual intercourse ) use two adequate non hormonal method contraception , include least one method failure rate &lt; 1 % per year , treatment period least 4 month last dose study drug . 29 . Continued : Examples nonhormonal contraceptive method failure rate &lt; 1 % per year include bilateral tubal ligation , male sterilization , establish , proper use hormonal contraceptive inhibit ovulation , hormonereleasing intrauterine device , copper intrauterine device . The reliability sexual abstinence need evaluate relation duration clinical trial prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 30 . History evidence thrombotic hemorrhagic disorder ; include cerebrovascular accident ( CVA ) / stroke transient ischemic attack ( TIA ) subarachnoid hemorrhage within &lt; /=6 month prior first study treatment . 31 . Uncontrolled hypertension ( sustain systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg despite antihypertensive therapy ) clinically significant ( i.e . active ) cardiovascular disease , include : myocardial infarction unstable angina within &lt; /=6 month prior first study treatment . New York Heart Association ( NYHA ) grade II great congestive heart failure ( CHF ) . serious cardiac arrhythmia require medication ( exception atrial fibrillation paroxysmal supraventricular tachycardia ) . Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior study enrollment . Prior history hypertensive crisis hypertensive encephalopathy . 32 . History bowel obstruction , include subocclusive disease , relate underlying disease history abdominal fistula , gastrointestinal perforation intraabdominal abscess . Evidence rectosigmoid involvement pelvic examination bowel involvement CT scan clinical symptom bowel obstruction . 33 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 34 . History hemoptysis ( &gt; /= 1/2 teaspoon bright red blood per episode ) within 1 month study enrollment tumor type . 35 . Nonhealing wound , ulcer bone fracture . 36 . Known hypersensitivity study drug excipients . 37 . Evidence medical condition ( psychiatric illness , peptic ulcer , etc . ) , physical examination laboratory finding may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malignant neoplasm female genital organ</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Primary Peritoneal Cancer</keyword>
	<keyword>relapsed/refractory</keyword>
	<keyword>Platinum-resistant disease</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>Emactuzumab</keyword>
	<keyword>RO5509554</keyword>
</DOC>